Evidence map›Paper›PMID 41866875›Full record

ReviewThe Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology2025

Expert Opinion on the Efficacy and Safety of Antispasmodics with a Focus on Irritable Bowel Syndrome.

Serhat Bor, Hasan Özen, İsmail Hakkı Kalkan, Filiz Akyüz, Altay Çelebi, Dinç Dinçer, Yusuf Serdar Sakin

Abstract readReview
In one paragraph

Review in The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Serhat BorDepartment of Gastroenterology, Ege University Faculty of Medicine, İzmir, Türkiye.ORCID 0000-0001-5766-9598
Hasan ÖzenDepartment of Pediatric Gastroenterology, Hepatology and Nutrition, Hacettepe University Faculty of Medicine, Ankara, Türkiye.ORCID 0000-0002-2349-1602
İsmail Hakkı KalkanDepartment of Gastroenterology, TOBB University of Economics and Technology School of Medicine, Ankara, Türkiye.ORCID 0000-0003-3871-9814
Filiz AkyüzDepartment of Gastroenterology, İstanbul University İstanbul Faculty of Medicine, İstanbul, Türkiye.ORCID 0000-0001-7498-141X
Altay ÇelebiDepartment of Gastroenterology, Kocaeli University School of Medicine, Kocaeli, Türkiye.ORCID 0000-0003-2864-7124
Dinç DinçerDepartment of Gastroenterology, Akdeniz University School of Medicine, Antalya, Türkiye.ORCID 0000-0001-6769-9344
Yusuf Serdar SakinDepartment of Gastroenterology, Acıbadem Kent Hospital, İzmir, Türkiye.ORCID 0000-0002-3896-0934

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Antispasmodics are commonly used to treat irritable bowel syndrome (IBS) symptoms. They are generally regarded as safe.However, some have been found to be ineffective or not cost-effective. Marked discrepancies in the availability and formulation of antispasmodic agents across countries—ranging from the limitation to only fundamental compounds in regions such as the United States to the marketing of diverse combination products elsewhere—have generated considerable ambiguity and debate within the field. Meta-analyses show varying results on the efficacy of antispasmodics, indicating the need for further analysis. This article aims to evaluate the effectiveness of antispasmodic drugs in relieving symptoms in IBS patients. We conclude that most drugs are considered safe and effective, with pinaverium, otilonium, and peppermint oil having meta-analyses supporting their efficacy. However, there is a lack of high-quality data for drugs like alverine, trimebutine, and cimetropium, and some drugs, such as simeticone or combinations of spasmolytic agents and simeticone, have insufficient research data. Clinicians should prioritize evidence-based medicine when selecting antispasmodic agents.

Indexed as

Irritable Bowel SyndromeParasympatholyticsHumansMentha piperitaMeta-Analysis as TopicMorpholinesPlant OilsQuaternary Ammonium CompoundsTreatment OutcomeMorpholinesoctyloniumParasympatholyticspeppermint oilpinaveriumPlant OilsQuaternary Ammonium Compounds

Identifiers

PMID41866875
PMCPMC13007261

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.